Clinical trials: Patients With Diabetes.
Diabetes Type 1
A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes
The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an external continuous subcutaneous insulin infusion system in adult participants with type 1 diabetes.
- Trial name
- PRONTO-Pump (NCT03433677)
- Testing
- LY900014, Insulin lispro
- Where
- 5 sites in United States, Spain
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Atherosclerotic Cardiovascular Disease, Type 2 Diabetes
High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes
To assess the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe compared to high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with type 2 diabetes
- Trial name
- NCT03403556
- Testing
- Rosuvamibe, Monorova
- Where
- 6 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Yuhan Corporation
Diabetes Mellitus, Type 2
Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
Reduced factorial design study with 24 week randomized treatment of initial combination therapy with linagliptin and metformin in T2DM patients
- Trial name
- NCT01708902
- Testing
- linagliptin2.5mg/metformin1000mg, linagliptin 5mg, Metformin 500mg
- Where
- 56 sites in China, Malaysia and 2 more
- Volunteers
- 876 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes
The purpose of this study is to compare Lispro Mixture Therapy (insulin lispro 50/50 given three times daily with meals) to Glargine Basal-Bolus Therapy (insulin glargine daily with the addition of insulin lispro given three…
- Trial name
- NCT00110370
- Testing
- Lispro Mixture Therapy, Glargine Basal-Bolus Therapy
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.
- Trial name
- NCT04450394
- Testing
- LY3209590, Insulin Degludec
- Where
- 64 sites in United States, Argentina and 3 more
- Volunteers
- 278 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study in Patients With Type 2 Diabetes
The study is designed to see if once daily oral dosing of LY2608204 will help control diabetes as measured by the glycosylated fraction of hemoglobin A (HbA1c) level.
- Trial name
- NCT01408095
- Testing
- LY2608204, Glimepiride
- Where
- 38 sites in United States, Austria and 5 more
- Volunteers
- 240 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients
The purpose of this study is to obtain information on PK/PD, efficacy and safety of SHR3824 over 12 weeks in Chinese patients with Type 2 Diabetes.
- Trial name
- NCT02366351
- Testing
- SHR3824
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Retinal Vasculitis
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice.
- Trial name
- NCT06769412
- Testing
- aflibercept 2 mg
- Where
- United States
- Volunteers
- 550,000 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetes Mellitus Type 2
A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator (2) in combination with metformin, compared to that of placebo (metformin monotherapy), in patients with type 2 diabetes mellitus.
- Trial name
- NCT00266253
- Testing
- GK Activator (2), Metformin
- Where
- 47 sites in United States, Australia and 4 more
- Volunteers
- 220 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably > 1500 mg metformin in patients with…
- Trial name
- NCT00622284
- Testing
- BI 1356, Glimepiride
- Where
- 221 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,560 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes Mellitus
IMCY-T1D-002: Long-term Follow-up Study of T1D Patients Previously Treated With IMCY-0098 or Placebo
This study is the follow-up of study IMCY-T1D 001 (EudraCT: 2016-003514-27, NCT03272269) in which patients with recent onset T1D have been treated with IMCY-0098 or placebo.
- Trial name
- IMCY-T1D-002 (NCT04190693)
- Where
- 19 sites in Belgium, Denmark and 5 more
- Volunteers
- 30 people
- Sponsor
- Imcyse SA
Diabetic Macular Edema, Diabetic Retinopathy
Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
The purpose of this study is to determine the safety and tolerability of MS-R001 at escalating doses in patients with diabetic macular edema secondary to diabetic retinopathy
- Trial name
- NCT00401115
- Testing
- MS-R001 (rapamycin)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Santen Inc.
Diabetes Mellitus, Type 2
ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)
This is a prospective 24-week, randomized, parallel-group, multi-center, active-controlled (pioglitazone 45 mg) open-label study designed to assess the effects of tesaglitazar 2 mg per day on components of renal excretion of…
- Trial name
- NCT00229684
- Testing
- Tesaglitazar, pioglitazone
- Where
- 21 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus
Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus
Primary Objective: To assess the safety and tolerability of two dose levels of a new insulin glargine formulation in a once-daily multiple dosing regimen Secondary Objective: To compare the pharmacokinetic and pharmacodynamic…
- Trial name
- NCT01349855
- Testing
- Insulin glargine HOE901
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Sanofi
Chronic Renal Insufficiency, Type 2 Diabetes Mellitus
A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)
This is a 2-part study in participants with renal impairment and matched healthy participants to investigate the effect of impaired renal function on the plasma and urine levels of omarigliptin (MK-3102) after taking a single 3…
- Trial name
- NCT01407276
- Testing
- Omarigliptin
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type II Diabetes
The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients
The purpose of this study is to test the efficacy of PAZ320 in diabetic patients.
- Trial name
- PAZ320 (NCT04569214)
- Testing
- PAZ320
- Where
- France
- Sponsor
- Boston Therapeutics
Diabetes Mellitus, Insulin-Dependent
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes
The objective of this clinical trial is to investigate whether ladarixin has sufficient activity (preservation of β-cell function and slow-down of the progression of T1D) to warrant its further development (proof of concept…
- Trial name
- NCT02814838
- Testing
- Ladarixin
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 76 people
- Sponsor
- Dompé Farmaceutici S.p.A
Type 2 Diabetes Mellitus, Hypercholesterolemia
A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)
The purpose of this 10-week study is to compare the reduction in cholesterol following treatment with two different marketed drugs, in patients with type 2 diabetes mellitus and hypercholesterolemia.
- Trial name
- NCT00110435
- Testing
- MK0653A, ezetimibe (+) simvastatin, Comparator: atorvastatin
- Volunteers
- 1,229 people
- Sponsor
- Organon and Co
Diabetes Mellitus, Type 1
Evaluation of Accu-Chek DiaPort, a Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes
The Accu-Chek DiaPort system enables continuous intraperitoneal insulin infusion (CIPII): that is, infusion of insulin into the peritoneal cavity using an Accu-Chek insulin pump and an infusion set.
- Trial name
- NCT01483352
- Testing
- Accu-Chek DiaPort
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease, Type 2 Diabetes
Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
This study assesses the effects of bardoxolone methyl (RTA 402) in patients with type 2 diabetes and chronic kidney disease.
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes, Diabetic Nephropathy
- Trial name
- NCT00811889
- Testing
- Bardoxolone Methyl (RTA 402)
- Where
- 42 sites in United States
- Volunteers
- 227 people
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.